4D Pharma Joins The SPAC Trend To Fund Its Keytruda-Boosting Biotherapeutic
A Platform To Attract More Investors
The Leeds, UK-based company is looking to the alternative route to the US stock market to fund its live biotherapeutics platform.
You may also be interested in...
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
A rush of additional orders from countries around the world has boosted the company’s prospects, and fueled its ambitions beyond COVID-19.